INTRODUCTION
Identification and structural characterization of the agonistbinding domain of ligand-gated ion channels is a major focus of molecular pharmacology. A prominent model system for these studies is the vertebrate muscle nicotinic acetylcholine (ACh) receptor (AChR). This receptor is a pentamer comprised of four subunits in a stoicheiometry of a2/?y&; each receptor is known to contain two ACh-binding sites [1] . Studies using affinity-labelling techniques demonstrated agonist-protectable covalent modification of cysteines at positions 192 and 193 , and tyrosines at positions 190 and 198 of the a-subunit [2] [3] [4] . Western blotting using the competitive antagonist a-bungarotoxin, together with studies employing synthetic peptides, has confirmed that the region ofthe a-subunit between amino acids 173 and 201 contains major determinants of the agonist-binding site [5] . Affinity labelling has also identified two other regions of the a-subunit where lower levels of agonist-protectable labelling suggested a proximity ta the ACh-binding site, at Tyr-93 and Trp-149 [6, 7] . On the basis of these data, Dennis and colleagues [3] proposed a three-loop model in which three discontinuous regions of the asubunit each participate in formation of the ACh-binding pocket. Another proposed model, based on electron microscopy of AChR from Torpedo, also suggests that the agonist-binding sites are completely contained within the a-subunits [8] . However, no model that includes only a-subunits can easily account for the differences in binding characteristics of the two agonist-binding sites. 193. Only one mutation, aYl98C, caused dramatic changes in the EC50 for acetylcholine (ACh) and in the sensitivity to DTT. We then examined the effects of the thiol modification and found two mutants, acHl86C and aVI88C, that showed significant decreases in responsiveness to ACh after exposure to methylmethanethiosulphonate (MMTS). Dose-response measurements show that exposure of aHl86C mutants to MMTS causes a shift in apparent agonist affinity without changing the peak response, and this is not reversible by DTT. In contrast, the MMTStreated aV188C mutants show changes in both apparent affinity and peak response which are readily reversed by DTT. Together, our data show that these two nearby residues occupy markedly different environments relative to the contact points for ACh. They also demonstrate that cysteine-substitution mutagenesis can be successfully applied to protein domains that include functionally important disulphides.
More recent work has demonstrated that differences between the two agonist-binding sites are probably due to participation of the y-and 8-subunits. Studies of ay and ad assembly intermediates showed that differing antagonist affinities could be ascribed to the presence of y-or 8-containing dimers [9] . This finding was extended by functional studies of y-less and d-less AChRs expressed in vitro [10] , and by studies of y-& chimaeras [11] . In addition, Czajkowski and Karlin [12] used a heterobifunctional cross-linker to show that a negatively charged residue in the d-subunit was within 0.1 nm (10 A) of the cysteine pair at positions 192 and 193. Together, these studies have led to models of the ACh-binding sites which presume that agonistbinding sites lie at the a-y and a-d subunit interfaces [13] .
The combination of site-directed mutagenesis and heterologous expression has confirmed the importance of residues implicated by biochemical techniques in the interaction of agonists with the receptor. Positions in the a-subunit at which substitution has been shown to alter functional responses include the tyrosines at positions 190, 198 and 93, and the tryptophan at position 149 [14] [15] [16] . Functional analysis of mutants has also been used to confirm the importance of residues in the y-and 8-subunits in determining binding characteristics of ACh [17] and curare [13] . Although the combination of mutagenesis and heterologous expression has provided information on the participation of specific residues in the process of agonist binding and activation, it does not directly allow for detailed modelling of secondary or tertiary structure of the binding site, nor does it provide data on conformational changes accompanying binding [18] , lac permease [19] and carbonic anhydrase II [20] . The unique chemical reactivity of free thiol groups provides a target for chemical modification, as shown by studies of the channelforming domain of the AChR [21] . Free thiol groups can also be used to create sites for metal ion binding [22] or allow formation of intra-or inter-molecular disulphide bonds [23] . As a first step toward application of this technique to the AChR agonistbinding domain, we prepared and characterized a series of mutant a-subunits with a single cysteine substituted between positions 183 and 198.
EXPERIMENTAL Mutagenesis and in vitro RNA preparation
The pSP64-based plasmids containing the cDNAs for the a-, /J-, y-and 8-subunits of the mouse muscle nicotinic AChR were provided by Dr. J. Boulter (Salk Institute, La Jolla, CA, U.S.A.). The a-subunit cDNA was subcloned into a pSP64 plasmid containing Xenopus globin non-coding sequence (designated pSP64T [24] ). Mutations were introduced into an a-subunit cDNA subcloned into pBluescript (Stratagene, La Jolla, CA, U.S.A.) using oligonucleotide-directed mutagenesis [25] . Mutations were confirmed by DNA sequencing [26] , and the 800 bp Bsu36I-BglII fragment of the cDNA containing the mutation was subcloned into the a-pSP64T plasmid. RNAs encoding wild-type and mutant receptor subunits were transcribed as described previously [14] . After synthesis, RNA was purified with the RNAid kit (BiolOl, La Jolla, CA, U.S.A.). Individual subunit RNAs were mixed in a ratio of 2a: 1,: ly: 18, and injected into Xenopus laevis oocytes as described previously [14] . Injected oocytes were maintained in ND-96 (96 mM NaCl, 5 mM KCI, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM Hepes/NaOH, pH 7.6) at 17 'C.
Electrophyslology
Whole oocyte currents were recorded 1-3 days after injection by two-electrode voltage clamp using an OC-725B amplifier (Warner Instruments, Hamden, CT, U.S.A.). Oocytes were continuously perfused with a modified low-Ca2l saline (96 mM NaCl, 5 remaining mutant a-subunits appear to assemble with ,-, y-and d-subunits to form functional AChRs at levels comparable with that of the wild-type a-subunit. One of our major concerns was the possible disruption of the structure of the binding site as the result of formation of disulphide bonds between introduced cysteines and the native cysteines at positions 192 and 193. This was of particular concern in those mutants in which the apparent agonist affinity was markedly different from the wild type. To examine this we looked at the effects of the reducing agent DTT on currents elicited by a half-maximal concentration of ACh for both wildtype and mutant AChRs, as shown in Figure 2 . It is well established that DTT reduction of the disulphide between aC 192 and aC193 dan inhibit the Torpedo AChR [27] ; we find that inhibition of the wild-type AChR expressed in oocytes is seen after brief exposure to 5 mM DTT, but not to 1 mM DTT. With the exception of the aY198C mutant, the sensitivity of all cysteine mutants to DTT resembles that ofthe wild-type receptor: little or no inhibition at 1 mM DTT, and substantial inhibition at 5 mM DTT.
In contrast with the other cysteine mutants, a brief exposure of the aY I 98C mutant to 1 mM DTT produces a significant increase in the ACh-evoked current (Figure 2) . Exposure of the aY198C mutant to 5 mM DTT, however, gives rise to a substantial decrease in ACh responsiveness similar to that seen with the wild-type. We examined the nature of the DTT effect on this mutant further by comparing dose-response profiles of wild-type and aY198C receptors before and after exposure to 1 mM DTT, as shown in Figure 3 . The effect of 1 mM DTT on the aY198C is largely one of an increase in the peak current, with very little effect on the EC50 for activation. Lower concentrations of reducing agent (< 1 mM) had negligible effects on both the wild type and the other cysteine-substitution mutants, suggesting that the biphasic nature of the DTT effect was unique to the aY198C mutation.
We next wanted to test whether any of the cysteine-substitution mutations were sensitive to modification by a thiol-specific Figure 4 . MMTS exposure has little or no effect on the ACh responses of wild-type AChRs and most of the cysteine-substitution mutations. We cannot at present distinguish between two explanations for the absence of an effect in these cases: either the modification does not occur, or it occurs but has no effect on receptor function. The ACh responses of three mutants, aHl86C, aVl88C and aYI98C, are significantly inhibited after exposure to MMTS. Two of these mutants, acHl86C and aVI88C, were analysed further, as shown in Figure 5 . We looked at changes in both the EC50 and the maximal response for ACh after MMTS treatment.
We also examined the extent to which these effects were reversible by low concentrations of DTT, since the mixed disulphide formed by reaction between MMTS and the cysteine should be readily reducible.
AChRs with the aH186C mutation show a rightward shift in the dose-response curve, but little effect on the peak response elicited by ACh ( Figure Sb) . The effect of modification is not reversed by DTT. The effects of MMTS on the aVI 88C mutation are qualitatively different from those seen with the acHl86C mutant (Figure 5c ). In this case, modified receptors display a rightward shift in EC50, and a decrease in the maximal response to ACh; both of these effects are at least partially reversed by exposure to 1 mM DTT.
DISCUSSION
Structural analysis of AChRs, as with other multimeric integral membrane proteins, is severely limited by an inability to apply Xray-crystallographic and magnetic-resonance techniques that have been successfully used in studies of smaller soluble proteins. In this report we have described our initial results using cysteinesubstitution mutagenesis to investigate AChR structure and function. This method should allow us to apply a number of biochemical and spectroscopic techniques to examine these further. We have focused our initial efforts on the a-subunit domain which is likely to include major structural determinants of the ACh-binding site.
The fact that most of the substitutions do not significantly alter functional properties of the receptor indicates that we have not dramatically altered the three-dimensional structure of the binding site. This was a particular concern because of the presence of a critical disulphide in this region. Two of the 14 mutants are exceptions to this conclusion: aY 198C and aY 190C. We are not surprised that these two positions were the most sensitive to cysteine substitution; previous site-directed mutation of these conserved tyrosines has demonstrated their importance in agonist activation. The apparent absence of functional AChRs with the aY19OC mutation was somewhat surprising, given a previous report of the expression of this mutation in transfected mammalian cells [28] .
The aY198C mutant exhibited a distinct and unusual increase in peak response after exposure to DTT, and also displayed an EC50 for agonist two orders of magnitude higher than that of the wild type. One possible explanation for this result is that some of the mutant receptors have an aberrant disulphide between C198 and one of the native cysteines at positions 192 At its simplest, the process of agonist activation of the AChR can be thought of as a two-step process: binding of ACh and the conformational change between closed and open states of the liganded channel. Observed changes in dose-response relationships can be due to changes in either, or both, of these steps [29, 30] . Because the efficacy of ACh for the wild-type channel is high (open/closed ratio for liganded AChR is approx. 14 [31] ), chemical modifications (or mutations) which simply shift the dose-response curve can be due to a change in either of the two steps. The effect of MMTS modification at acH186C is such a case; for this mutant, we cannot distinguish an effect on binding from an effect on efficacy. In contrast, the MMTS-treated aV188C mutant exhibited both a shift in EC50 and a decline in the peak current. The change in peak current, particularly in-the light of the normally high efficacy of ACh, indicates that the modification has altered the ability of the receptor to undergo the closed-to-open transition. Thus, although the two sites (186 and 188) are separated by only a single residue, it is possible that the inhibition resulting from MMTS modification could be due to effects on two different steps in the activation process: inhibition of ACh binding (aHI86C) and inhibition of the closed-to-open transition (ocVI88C).
Modification ofthe aH186C and aV188C mutations by MMTS can also be distinguished in terms of their relative reversibility by DTT. In the case of the alH186C mutant, we find that the effect of modification is not reversed by 1 mM DTT. This could be due to an 'irreversible' change in receptor conformation or a change in accessibility of the residue after modification, such that the DTT would not have access to the thio-methyl adduct. The effect of modification of the aV188C mutant is, in contrast, substantially reversible by 1 mM DTT. These observations are consistent with a mechanistic distinction between the effects of MMTS on these two cysteine substitutions.
MMTS concentrations as low as 250 ,tM produce the same effects as higher concentrations on both acHl86C and aV188C, suggesting that the extent of modification we observe is complete and not limited by MMTS concentration or by reaction time (results not shown). Nevertheless, our results could be explained by a heterogeneous population of partially, completely and unmodified receptors that have distinct dose-response profiles. For example, modification of the aV188C mutant at only one of the two a-subunits could cause a shift in the dose-response curve to the right, whereas complete modification could abolish agonistdependent activation (reducing the peak response Single-channel analysis of the cysteine mutations, both before and after exposure to modifying reagents, should help to clarify the underlying changes responsible for our observations. Site-directed mutagenesis has become an important tool in the identification of residues critical to ion channel structure and function; despite this, interpretation of results from such experiments is not always straightforward. One of the most significant advantages of the cysteine-substitution technique is that it allows for examination of the same population of channels before and after modification. In this sense, chemical modification of engineered cysteines may be thought of as in situ or real-time mutagenesis. This, together with the many biochemical tools available for characterization of cysteines, promises to make cysteine-substitution mutagenesis an important approach to elucidating the structure and function of ligand-gated channels such as the AChR.
